
Deep LS uses AI to accelerate drug discovery and optimization. It operates as a pharmaceutical research SaaS platform that applies AI, machine learning, deep learning, graph neural networks (GNNs), and large language models (LLMs) to design ligands, evaluate toxicity and solubility, and identify binding sites on targets. Its offerings include platforms like GeneSys and projects such as the Chemical Space Navigator, Plant Graph Target Discovery, and RNA Ligand Diffusion. The approach blends pharma expertise with data science to improve efficiency, reduce costs, and minimize waste in the drug discovery pipeline. Typical customers are pharmaceutical and biopharmaceutical researchers seeking computational, AI-driven drug discovery solutions.

Deep LS uses AI to accelerate drug discovery and optimization. It operates as a pharmaceutical research SaaS platform that applies AI, machine learning, deep learning, graph neural networks (GNNs), and large language models (LLMs) to design ligands, evaluate toxicity and solubility, and identify binding sites on targets. Its offerings include platforms like GeneSys and projects such as the Chemical Space Navigator, Plant Graph Target Discovery, and RNA Ligand Diffusion. The approach blends pharma expertise with data science to improve efficiency, reduce costs, and minimize waste in the drug discovery pipeline. Typical customers are pharmaceutical and biopharmaceutical researchers seeking computational, AI-driven drug discovery solutions.
What they do: AI-driven drug discovery (generative ligand design, optimization, binding-site ID)
Core product: GeneSys platform for generative molecule/ligand design
Founded / HQ: Founded 2021; Limburg an der Lahn, Hessen, Germany
Founders: Daniel Soric; Felix Kamieth
Computational drug discovery and molecular design
2021
Biotechnology